Full-Time

Associate Director – Site Data Integrity and Computer System Validation Lead

Posted on 4/11/2026

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$111k - $178.2k/yr

+ Bonus

Pleasant Prairie, WI, USA

In Person

Onsite presence required; flex time available.

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Requirements
  • Bachelor's degree required; engineering or computer science-related field preferred
  • Minimum 5 years working in the pharmaceutical or medical device industry in QA roles
  • Minimum 3 years of experience in Computer System Quality Assurance/Computer System Validation
  • Minimum 3 years of experience with data analytics including advanced analytics
Responsibilities
  • The Site Data Leader will have primary responsibility for data management activities within the Lilly Kenosha County (LKC) site.
  • The Site Data Leader is an advocate for data management across the manufacturing site and chairs the site data lead team.
  • The Site Data Leader ensures a robust Data Integrity Program exists and is maintained within the site providing strong project management leadership to advance the site’s agenda.
  • This requires interface with the M&Q Data Management organization, serving as a global data management subject matter expert to facilitate and drive improvements in M&Q data-related corporate quality standards, business processes, organizational design, and governance necessary for ongoing data integrity effectiveness.
  • This role will partner with functional area data experts to anticipate and resolve key data management and integrity issues while driving solutions that impact the site and align with corporate objectives.
  • The Associate Director, Quality Assurance, will also provide computer system quality assurance oversight during the start-up and routine operation of the Lilly Kenosha County site.
  • In addition, this role will transition to a site-based data management and analytics leader role for routine production.
  • This role will leverage a deep understanding of GMP data flows (electronic and paper), the application of data management and integrity principles in operational processes, and Computer System Validation methodologies to ensure regulatory compliance, consistency, and sustainment.
  • The Site Data Leader is responsible for ensuring the education and continuous knowledge on data integrity and data management at the site.
  • This role influences improving data management standards to ensure consistency and consumability of data to drive process improvements.
  • This role ensures compliance and inspection readiness of the data integrity and data management program at the site level.
  • The Site Data Leader is responsible for ensuring the site’s data integrity training program facilitates the sustainment of its data integrity continuous improvement journey.
  • The Site Data Leader reports to the Site Quality Leader and has dotted-line accountability to Global Data Management leadership.
  • This is an individual contributor role with responsibility for technical leadership, as well as project management.
  • Develop and maintain a comprehensive and integrated data integrity and data management program:
  • Facilitate the Site Data Lead Team
  • Partner with global and site leadership to ensure data integrity initiatives are given appropriate priority and cross functional resources.
  • Partner with functional site data subject matter experts (SMEs) to ensure that data management actions are completed in accordance with established plan.
  • Ensure completion and maintenance of Data Flow Maps as applicable to identify data integrity risks and define mitigation strategies.
  • Ensure programs are in place to facilitate and support data integrity improvements to documents, systems, and processes (e.g., audit trail reviews, user access, walk-throughs, Site Self Inspection).
  • Implement defined data standards (e.g., data structure, metadata) and usage guidelines as information passes through multiple systems / functions and ensure processes are in place to manage the data throughout its lifecycle.
  • Implement data strategy actions (e.g., digitization, contextualization, visualization) to enable appropriate use of data at the appropriate time to enable robust decision making, drive productivity, and facilitate continuous improvement.
  • Lead initiatives related to data integrity and data management for GMP information at the site:
  • Own site actions associated with the enterprise data management and integrity initiatives.
  • Maintain site data management metrics and track status of the data integrity action plans; report the status to the Site Data Lead Team.
  • Provide direction on the operationalization of the data management action plan including the transition from paper-based processes to digitized solutions.
  • Own the responsibility for enhancing and sustaining data management and integrity principles throughout the data lifecycle.
  • Own the development, maintenance, and be accountable for the implementation of the site Data Integrity Strategy
  • Ensure continuous professional development, education, training and knowledge transfer of data integrity and data management principles:
  • Participate in the design and delivery of learning opportunities for personnel with the purpose of strengthening the global M&Q Quality Culture as it relates to data management and integrity.
  • Provide training, coaching, feedback, and mentoring to personnel on data management and integrity principles and regulations.
  • Ensure compliance and inspection readiness of the data integrity and data management program at the site level:
  • Coach individuals on inspection interactions.
  • Lead preparation of data integrity and data management topics for audit and inspection readiness.
  • Network with other sites and central groups to understand external and company trends and develop internal improvement plans.
  • Ensure inspection readiness for regulatory authority inspections and effectively represent the company during regulatory audits through interaction / discussion with regulatory officials related to data integrity expertise in areas as necessary.
  • Ensure compliance with applicable Lilly global standards and regulatory guidelines.
  • Participate in data management and integrity assessments of current-state practices, procedures, system functionality, including but not limited to physical and logical security, Electronic Records / Electronic Signatures (ER / ES), audit trails, data mapping, records / data backup, archive and retention, computer system validation, infrastructure qualification, investigation, and training programs.
  • Act as site liaison and representative for the data integrity and data management program.
  • Serve as the site liaison with the Global Data Management organization forming the data community of practice; provide feedback to the global organization for opportunities or concerns.
  • Serve as a global data management subject matter expert to facilitate and drive improvements in M&Q data-related corporate quality standards, business processes, organizational design, and governance necessary for ongoing data integrity effectiveness.
  • Utilize site data management expertise to solve problems both locally and across global M&Q.
  • Act as the Computer systems validation quality assurance project lead, working with Global Facility Delivery and Lilly project staff to complete the detailed design of the assigned areas employing QbD and QRM principals and ensuring the integration of Global Quality System requirements into the design.
  • Responsibilities include:
  • Consult with Network and Global quality groups including the Global Quality Systems, Information Systems Quality, and Global Data Management as required to ensure consistent and compliant approach is executed during the project and startup phase
  • Provide technical and quality review and approval of project computer system documents to ensure compliance with Lilly Global Quality Standards as well as project and local quality procedures, including review of test cases, test execution, discrepancy resolution, etc.
  • Work with the Associate Director, Quality - Compliance, to support the development of the vision and strategy for the overall site quality operation with focus on the CSQA topics
  • Support the site organization in building technical capability, for a diverse cross-functional staff in Quality, the project team, and area process teams, including mentoring of new Quality and other project staff
  • Lead project initiatives needed in support of the project and Quality function
  • Resolve or escalate any compliance issues to the project, site, and Quality Management
  • Participate in self-led inspections and provide support during internal/external regulatory inspections
  • Ensure data integrity by design
  • Leverage technology to ensure data digitalization and standardization where appropriate
  • Design, replicate and employ analytics and advanced analytics for competitive advantage within the site
Desired Qualifications
  • Demonstrated successful leadership of cross-functional teams and project management experience
  • Demonstrated proficiency with GMP computer systems validation including regulations governing them
  • Demonstrated knowledge and application of data integrity regulatory guidance
  • Proven ability to apply analytics and advanced analytics for competitive advantage within a manufacturing operation
  • Demonstrated strong oral and written communication
  • Strong self-management and organizational skills
  • Demonstrated strong interpersonal interaction skills and ability to influence cross-functional organizations
  • Demonstrated strong technical writing skills
  • Demonstrated strong problem-solving and decision-making skills
  • Has previous facility or area start up experience
  • Has previous qualification and validation experience (process automation and/or IT systems)
  • Has previous Six Sigma Green Belt or Lean Training/Experience
  • Has CQA certification from the American Society for Quality (ASQ) - preferable

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • International Mounjaro sales jumped to $4.4 billion in Q1 from China's reimbursement list.
  • $4.5 billion Lebanon API plant opens 2027, producing tirzepatide and retatrutide at largest scale.
  • Acquires Scorpion's PI3Kα inhibitor, bolstering oncology pipeline beyond Verzenio.

What critics are saying

  • Novo Nordisk's Wegovy scaling erodes Lilly's US GLP-1 share below 25% into 2027.
  • FDA scrutiny delays Foundayo launch after May 4 hepatic failure, losing $2-3B Q4 revenue.
  • Shareholder demands force independent board chair, dropping stock 10-15% in 12 months.

What makes Lilly USA unique

  • Mounjaro generated $8.66 billion in Q1 2026 sales, surpassing Keytruda as world's best-selling drug.
  • Launched first genetic medicine facility in Lebanon on May 6, 2026, for Alzheimer's and ALS.
  • Partnered with Profluent Bio for up to $2.25 billion AI-driven DNA editing tools on May 5.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE